Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma Intervention:   Drug: ADI-PEG20 Sponsor:   Chang Gung Memorial Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials